以α -2b为基础的干扰素联合用药在冠状病毒感染后疱疹性角膜炎综合治疗中的应用

A. Surov, M. Medvedeva, S. F. Sagirova, T. Konstantinova, L. V. Gabatova, O. G. Moroz
{"title":"以α -2b为基础的干扰素联合用药在冠状病毒感染后疱疹性角膜炎综合治疗中的应用","authors":"A. Surov, M. Medvedeva, S. F. Sagirova, T. Konstantinova, L. V. Gabatova, O. G. Moroz","doi":"10.21516/2072-0076-2023-16-2-83-91","DOIUrl":null,"url":null,"abstract":"Purpose: to assess the effectiveness of the combined interferon alpha-2b-based medicine (Ophtalmoferon, eye drops) in the complex treatment of herpetic keratitis in patients who had coronavirus infection caused by SARS-CoV-2.Materials and methods. The study group included 53 people aged 18 to 74 years (mean age 46.0 ± 7.8 years) with the following complaints: decreased vision, redness, eye pain, lacrimation, photophobia and foreign body sensation under the eyelid. Criteria for selection and inclusion of patients were: typical for herpetic keratitis corneal infiltrates detected by biomicroscopy; herpetic infection detected by Polymerase Chain Reaction (PCR) in the affected eye corneal scrape; a medical history of the novel coronavirus infection confirmed by PCR. The patients were divided into two groups. Group 1 (n = 32) received complex treatment with the combined interferon alpha-2b-based medicine (Ophtalmoferon®, eye drops) at early stages of the disease (from the 1st to 7th day after the first complaints). Group 2 (n = 21) received complex treatment with Ophtalmoferon® at later stages (from the 14th day of the first complaints). The effectiveness and tolerability of Ophtalmoferon were assessed during the dynamic monitoring of the patients.Results. A positive trend was noted in 79.2 % (n = 42) of all patients who received Ophtalmoferon for the complex treatment of herpetic keratitis: a gradual improvement in visual acuity, reduction or disappearance of photophobia, lacrimation and eye pain. In 20.8 % (n = 11) of all cases, mostly related to the late start of etiological therapy, the treatment effectiveness was lower, the disease lasted longer and was accompanied by the involvement of the choroid, the development of more severe opacities in the place of corneal infiltrates. Due to later start of etiotropic therapy the inflammatory process affected deeper layers of the cornea up to the development of corneal ulcer with perforation, which required surgical intervention.Conclusion. The etiotropic treatment of herpetic keratitis in patients after COVID-19, if started in the first days of the disease, can quickly stop the inflammatory process and prevent its spread to deeper layers of the cornea. Ophtalmoferon is a highly effective medicine for etiotropic treatment of keratitis caused by herpesviruses. Due to high patient compliance, Ophtalmoferon can be recommended for wide use in the complex therapy of herpetic keratitis.","PeriodicalId":36080,"journal":{"name":"Rossiiskii Oftal''mologicheskii Zhurnal","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The use of combined interferon alpha-2b-based medicine in the complex treatment of herpetic keratitis in patients after coronavirus infection\",\"authors\":\"A. Surov, M. Medvedeva, S. F. Sagirova, T. Konstantinova, L. V. Gabatova, O. G. Moroz\",\"doi\":\"10.21516/2072-0076-2023-16-2-83-91\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: to assess the effectiveness of the combined interferon alpha-2b-based medicine (Ophtalmoferon, eye drops) in the complex treatment of herpetic keratitis in patients who had coronavirus infection caused by SARS-CoV-2.Materials and methods. The study group included 53 people aged 18 to 74 years (mean age 46.0 ± 7.8 years) with the following complaints: decreased vision, redness, eye pain, lacrimation, photophobia and foreign body sensation under the eyelid. Criteria for selection and inclusion of patients were: typical for herpetic keratitis corneal infiltrates detected by biomicroscopy; herpetic infection detected by Polymerase Chain Reaction (PCR) in the affected eye corneal scrape; a medical history of the novel coronavirus infection confirmed by PCR. The patients were divided into two groups. Group 1 (n = 32) received complex treatment with the combined interferon alpha-2b-based medicine (Ophtalmoferon®, eye drops) at early stages of the disease (from the 1st to 7th day after the first complaints). Group 2 (n = 21) received complex treatment with Ophtalmoferon® at later stages (from the 14th day of the first complaints). The effectiveness and tolerability of Ophtalmoferon were assessed during the dynamic monitoring of the patients.Results. A positive trend was noted in 79.2 % (n = 42) of all patients who received Ophtalmoferon for the complex treatment of herpetic keratitis: a gradual improvement in visual acuity, reduction or disappearance of photophobia, lacrimation and eye pain. In 20.8 % (n = 11) of all cases, mostly related to the late start of etiological therapy, the treatment effectiveness was lower, the disease lasted longer and was accompanied by the involvement of the choroid, the development of more severe opacities in the place of corneal infiltrates. Due to later start of etiotropic therapy the inflammatory process affected deeper layers of the cornea up to the development of corneal ulcer with perforation, which required surgical intervention.Conclusion. The etiotropic treatment of herpetic keratitis in patients after COVID-19, if started in the first days of the disease, can quickly stop the inflammatory process and prevent its spread to deeper layers of the cornea. Ophtalmoferon is a highly effective medicine for etiotropic treatment of keratitis caused by herpesviruses. Due to high patient compliance, Ophtalmoferon can be recommended for wide use in the complex therapy of herpetic keratitis.\",\"PeriodicalId\":36080,\"journal\":{\"name\":\"Rossiiskii Oftal''mologicheskii Zhurnal\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rossiiskii Oftal''mologicheskii Zhurnal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21516/2072-0076-2023-16-2-83-91\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rossiiskii Oftal''mologicheskii Zhurnal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21516/2072-0076-2023-16-2-83-91","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的:评价以α -2b为基础的干扰素类药物(Ophtalmoferon、滴眼液)联合治疗SARS-CoV-2型冠状病毒感染的疱疹性角膜炎的疗效。材料和方法。研究组患者53例,年龄18 ~ 74岁(平均46.0±7.8岁),主诉为视力下降、红肿、眼痛、流泪、畏光、眼睑下异物感。患者的选择和纳入标准为:生物显微镜下发现典型的疱疹性角膜炎角膜浸润;聚合酶链式反应(PCR)检测角膜擦伤疱疹感染;经PCR证实的新型冠状病毒感染病史。患者被分为两组。第1组(n = 32)在疾病早期(首次主诉后第1 ~ 7天)给予干扰素-2b类药物(Ophtalmoferon®,滴眼液)联合治疗。第二组(n = 21)在晚期(首次主诉第14天起)接受复方治疗。在患者动态监测的过程中,评价了眼啡酮的疗效和耐受性。79.2% (n = 42)接受optalmoferon复合治疗的疱疹性角膜炎患者有积极的趋势:视力逐渐改善,近视、流泪和眼痛减少或消失。20.8% (n = 11)的病例多与病因治疗开始较晚有关,治疗效果较低,病程较长,伴脉络膜受累,角膜浸润处混浊较严重。由于病因治疗开始较晚,炎症过程影响到角膜的较深层,直至角膜溃疡并穿孔,这需要手术干预。COVID-19患者的疱疹性角膜炎的病因治疗,如果在疾病的最初几天开始,可以迅速停止炎症过程,防止其扩散到更深的角膜层。眼铁素是一种治疗疱疹病毒引起的角膜炎的高效药物。由于患者的高依从性,Ophtalmoferon可广泛用于疱疹性角膜炎的综合治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The use of combined interferon alpha-2b-based medicine in the complex treatment of herpetic keratitis in patients after coronavirus infection
Purpose: to assess the effectiveness of the combined interferon alpha-2b-based medicine (Ophtalmoferon, eye drops) in the complex treatment of herpetic keratitis in patients who had coronavirus infection caused by SARS-CoV-2.Materials and methods. The study group included 53 people aged 18 to 74 years (mean age 46.0 ± 7.8 years) with the following complaints: decreased vision, redness, eye pain, lacrimation, photophobia and foreign body sensation under the eyelid. Criteria for selection and inclusion of patients were: typical for herpetic keratitis corneal infiltrates detected by biomicroscopy; herpetic infection detected by Polymerase Chain Reaction (PCR) in the affected eye corneal scrape; a medical history of the novel coronavirus infection confirmed by PCR. The patients were divided into two groups. Group 1 (n = 32) received complex treatment with the combined interferon alpha-2b-based medicine (Ophtalmoferon®, eye drops) at early stages of the disease (from the 1st to 7th day after the first complaints). Group 2 (n = 21) received complex treatment with Ophtalmoferon® at later stages (from the 14th day of the first complaints). The effectiveness and tolerability of Ophtalmoferon were assessed during the dynamic monitoring of the patients.Results. A positive trend was noted in 79.2 % (n = 42) of all patients who received Ophtalmoferon for the complex treatment of herpetic keratitis: a gradual improvement in visual acuity, reduction or disappearance of photophobia, lacrimation and eye pain. In 20.8 % (n = 11) of all cases, mostly related to the late start of etiological therapy, the treatment effectiveness was lower, the disease lasted longer and was accompanied by the involvement of the choroid, the development of more severe opacities in the place of corneal infiltrates. Due to later start of etiotropic therapy the inflammatory process affected deeper layers of the cornea up to the development of corneal ulcer with perforation, which required surgical intervention.Conclusion. The etiotropic treatment of herpetic keratitis in patients after COVID-19, if started in the first days of the disease, can quickly stop the inflammatory process and prevent its spread to deeper layers of the cornea. Ophtalmoferon is a highly effective medicine for etiotropic treatment of keratitis caused by herpesviruses. Due to high patient compliance, Ophtalmoferon can be recommended for wide use in the complex therapy of herpetic keratitis.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.50
自引率
0.00%
发文量
107
审稿时长
16 weeks
期刊最新文献
Telemedicine for glaucoma: the state-of-the-art and trends of development Modifying treatment of degenerative retinal diseases. Part 2. Conditioning therapy techniques and the problem of maximizing retinal plasticity Ocular proton therapy: state-of-the-art Methodological aspects of statistical analysis in ophthalmology Keratoprostheses: from the past to the future
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1